カテゴリ： Infiniti Research TechNavio, 世界, 医療/バイオ

世界の慢性閉塞性肺疾患治療薬市場2023～2027：併用療法、単剤療法

■ 英語タイトル：Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027

調査会社Technavio社が発行したリサーチレポート（データ管理コード：IRTNTR70733-23）■ 発行会社/調査会社：Technavio
■ 商品コード：IRTNTR70733-23
■ 発行日：2022年12月30日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：162
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,500 ⇒換算￥380,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD4,000 ⇒換算￥608,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の慢性閉塞性肺疾患治療薬市場2023～2027：併用療法、単剤療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Technavio社発行の当調査レポートは、世界の慢性閉塞性肺疾患治療薬市場規模が2022年から2027年まで年平均6.09%成長し、6654.49百万ドルに達すると予測しています。当レポートでは、慢性閉塞性肺疾患治療薬の世界市場について総合的に調査・分析を行い、エグゼクティブサマリー、市場状況、市場規模、過去の市場規模、ファイブフォース分析、製品別（併用療法、単剤療法）分析、販売チャネル別（病院薬局、小売薬局、オンライン薬局）分析、顧客状況、地域別状況（北米、ヨーロッパ、アジア太平洋、アメリカ、イギリス、カナダ、ドイツ、日本、その他地域）分析、推進要因・課題・動向、企業状況、企業分析などの内容をまとめております。なお、参入企業情報として、AstraZeneca Plc、Exela Pharma Sciences LLC、GlaxoSmithKline Plc、Glenmark Pharmaceuticals Ltd.、Innoviva Inc.、Lupin Ltd.、Merck and Co. Inc.、Mundipharma International Ltd.、Novartis AG、Theravance Biopharma Inc.、Vertex Pharmaceuticals Inc.、Viatris Inc.、Boehringer Ingelheim International GmbH、Cadila Pharmaceuticals Ltd.などが含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模
・過去の市場規模
・ファイブフォース分析

・世界の慢性閉塞性肺疾患治療薬市場規模：製品別
- 併用療法慢性閉塞性肺疾患治療薬の市場規模
- 単剤療法慢性閉塞性肺疾患治療薬の市場規模

・世界の慢性閉塞性肺疾患治療薬市場規模：販売チャネル別
- 病院薬局の市場規模
- 小売薬局の市場規模
- オンライン薬局の市場規模

・顧客状況

・地域別状況
- 北米の慢性閉塞性肺疾患治療薬市場規模
- ヨーロッパの慢性閉塞性肺疾患治療薬市場規模
- アジア太平洋の慢性閉塞性肺疾患治療薬市場規模
- アメリカの慢性閉塞性肺疾患治療薬市場規模
- イギリスの慢性閉塞性肺疾患治療薬市場規模
- カナダの慢性閉塞性肺疾患治療薬市場規模
- ドイツの慢性閉塞性肺疾患治療薬市場規模
- 日本の慢性閉塞性肺疾患治療薬市場規模
- その他地域の慢性閉塞性肺疾患治療薬市場規模

・推進要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要なパラメーターの分析によって得られた複数のソースからのデータを、調査・統合・総括することにより、市場の全体像を詳しく提示します。主要な業界のインフルエンサーを特定することにより、多様な市場の側面を提供します。これらのデータは包括的​​で信頼性が高く、一次・二次の広範な研究の結果です。Technavio社の市場調査書は、確かな市場の成長を予測するための定性的、定量的調査を行い、完全な競争状況、そして詳細なベンダー選択方法と分析を提供します。

慢性閉塞性肺疾患治療薬の世界市場 2023〜2027年

Technavio社は、慢性閉塞性肺疾患治療薬市場をモニターしており、2022年から2027年にかけて6,654.49百万ドルの成長が予測され、予測期間中のCAGRは6.09%で加速すると予測しています。当レポートでは、慢性閉塞性肺疾患治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、さらに約25のベンダーを網羅したベンダー分析などを提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供します。COPDの有病率の上昇、強力なパイプラインと新薬承認、合剤需要の拡大が市場を牽引しています。

Technavio社の慢性閉塞性肺疾患治療薬市場は以下のように分類されます：

・製品別：
– 併用治療薬
– 単剤治療薬

・流通チャネル別：
– 病院薬局
– 小売薬局
– オンライン薬局

・地域別：
– 北米
– ヨーロッパ
– アジア
– その他の地域（ROW）

本調査では、今後数年間における慢性閉塞性肺疾患治療薬市場の成長を牽引する主な要因の一つとして、治療アプローチの研究拡大を挙げています。また、ドラッグデリバリーデバイスの進歩や、禁煙のための電子タバコなどの利用拡大も、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、慢性閉塞性肺疾患治療薬市場について、以下の分野をカバーしています：
– 慢性閉塞性肺疾患治療薬市場のサイジング
– 慢性閉塞性肺疾患治療薬市場予測
– 慢性閉塞性肺疾患治療薬市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltdなどの企業情報が含まれています。また、慢性閉塞性肺疾患治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global chronic obstructive pulmonary disease drugs market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 – 2021 ($ million)
o 4.2 Product Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Product – Market share 2022-2027 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Combination therapy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
o 6.4 Monotherapy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Product
o Exhibit 42: Market opportunity by Product ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 43: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 45: Chart on Comparison by Distribution Channel
o Exhibit 46: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacies – Market size and forecast 2022-2027
o Exhibit 47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online pharmacies – Market size and forecast 2022-2027
o Exhibit 55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 59: Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 63: Chart on Geographic comparison
o Exhibit 64: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 65: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 67: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 68: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 81: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 85: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 93: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 97: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 101: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 102: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 104: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 105: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 106: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 107: Matrix on vendor position and classification
o 12.3 AstraZeneca Plc
o Exhibit 108: AstraZeneca Plc – Overview
o Exhibit 109: AstraZeneca Plc – Product / Service
o Exhibit 110: AstraZeneca Plc – Key news
o Exhibit 111: AstraZeneca Plc – Key offerings
o 12.4 Boehringer Ingelheim International GmbH
o Exhibit 112: Boehringer Ingelheim International GmbH – Overview
o Exhibit 113: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 114: Boehringer Ingelheim International GmbH – Key news
o Exhibit 115: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 116: Boehringer Ingelheim International GmbH – Segment focus
o 12.5 Cadila Pharmaceuticals Ltd.
o Exhibit 117: Cadila Pharmaceuticals Ltd. – Overview
o Exhibit 118: Cadila Pharmaceuticals Ltd. – Product / Service
o Exhibit 119: Cadila Pharmaceuticals Ltd. – Key offerings
o 12.6 Cipla Ltd.
o Exhibit 120: Cipla Ltd. – Overview
o Exhibit 121: Cipla Ltd. – Business segments
o Exhibit 122: Cipla Ltd. – Key news
o Exhibit 123: Cipla Ltd. – Key offerings
o Exhibit 124: Cipla Ltd. – Segment focus
o 12.7 Exela Pharma Sciences LLC
o Exhibit 125: Exela Pharma Sciences LLC – Overview
o Exhibit 126: Exela Pharma Sciences LLC – Product / Service
o Exhibit 127: Exela Pharma Sciences LLC – Key offerings
o 12.8 GlaxoSmithKline Plc
o Exhibit 128: GlaxoSmithKline Plc – Overview
o Exhibit 129: GlaxoSmithKline Plc – Business segments
o Exhibit 130: GlaxoSmithKline Plc – Key offerings
o Exhibit 131: GlaxoSmithKline Plc – Segment focus
o 12.9 Lupin Ltd.
o Exhibit 132: Lupin Ltd. – Overview
o Exhibit 133: Lupin Ltd. – Product / Service
o Exhibit 134: Lupin Ltd. – Key news
o Exhibit 135: Lupin Ltd. – Key offerings
o 12.10 Merck and Co. Inc.
o Exhibit 136: Merck and Co. Inc. – Overview
o Exhibit 137: Merck and Co. Inc. – Business segments
o Exhibit 138: Merck and Co. Inc. – Key news
o Exhibit 139: Merck and Co. Inc. – Key offerings
o Exhibit 140: Merck and Co. Inc. – Segment focus
o 12.11 Mundipharma International Ltd.
o Exhibit 141: Mundipharma International Ltd. – Overview
o Exhibit 142: Mundipharma International Ltd. – Product / Service
o Exhibit 143: Mundipharma International Ltd. – Key offerings
o 12.12 Novartis AG
o Exhibit 144: Novartis AG – Overview
o Exhibit 145: Novartis AG – Business segments
o Exhibit 146: Novartis AG – Key offerings
o Exhibit 147: Novartis AG – Segment focus
o 12.13 Shionogi and Co. Ltd.
o Exhibit 148: Shionogi and Co. Ltd. – Overview
o Exhibit 149: Shionogi and Co. Ltd. – Product / Service
o Exhibit 150: Shionogi and Co. Ltd. – Key offerings
o 12.14 Sumitomo Pharma Co. Ltd.
o Exhibit 151: Sumitomo Pharma Co. Ltd. – Overview
o Exhibit 152: Sumitomo Pharma Co. Ltd. – Business segments
o Exhibit 153: Sumitomo Pharma Co. Ltd. – Key offerings
o Exhibit 154: Sumitomo Pharma Co. Ltd. – Segment focus
o 12.15 Teva Pharmaceutical Industries Ltd.
o Exhibit 155: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 156: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 157: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 158: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 159: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.16 Theravance Biopharma Inc.
o Exhibit 160: Theravance Biopharma Inc. – Overview
o Exhibit 161: Theravance Biopharma Inc. – Product / Service
o Exhibit 162: Theravance Biopharma Inc. – Key offerings
o 12.17 Viatris Inc.
o Exhibit 163: Viatris Inc. – Overview
o Exhibit 164: Viatris Inc. – Business segments
o Exhibit 165: Viatris Inc. – Key offerings
o Exhibit 166: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 167: Inclusions checklist
o Exhibit 168: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 169: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 170: Research methodology
o Exhibit 171: Validation techniques employed for market sizing
o Exhibit 172: Information sources
o 13.5 List of abbreviations
o Exhibit 173: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global chronic obstructive pulmonary disease drugs market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Product – Market share 2022-2027 (%)
Exhibits31: Data Table on Product – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Combination therapy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Combination therapy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Monotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Monotherapy – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Product ($ million)
Exhibits43: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits44: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Distribution Channel
Exhibits46: Data Table on Comparison by Distribution Channel
Exhibits47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits59: Market opportunity by Distribution Channel ($ million)
Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits63: Chart on Geographic comparison
Exhibits64: Data Table on Geographic comparison
Exhibits65: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits67: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits68: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits101: Market opportunity By Geographical Landscape ($ million)
Exhibits102: Impact of drivers and challenges in 2022 and 2027
Exhibits103: Overview on Criticality of inputs and Factors of differentiation
Exhibits104: Overview on factors of disruption
Exhibits105: Impact of key risks on business
Exhibits106: Vendors covered
Exhibits107: Matrix on vendor position and classification
Exhibits108: AstraZeneca Plc – Overview
Exhibits109: AstraZeneca Plc – Product / Service
Exhibits110: AstraZeneca Plc – Key news
Exhibits111: AstraZeneca Plc – Key offerings
Exhibits112: Boehringer Ingelheim International GmbH – Overview
Exhibits113: Boehringer Ingelheim International GmbH – Business segments
Exhibits114: Boehringer Ingelheim International GmbH – Key news
Exhibits115: Boehringer Ingelheim International GmbH – Key offerings
Exhibits116: Boehringer Ingelheim International GmbH – Segment focus
Exhibits117: Cadila Pharmaceuticals Ltd. – Overview
Exhibits118: Cadila Pharmaceuticals Ltd. – Product / Service
Exhibits119: Cadila Pharmaceuticals Ltd. – Key offerings
Exhibits120: Cipla Ltd. – Overview
Exhibits121: Cipla Ltd. – Business segments
Exhibits122: Cipla Ltd. – Key news
Exhibits123: Cipla Ltd. – Key offerings
Exhibits124: Cipla Ltd. – Segment focus
Exhibits125: Exela Pharma Sciences LLC – Overview
Exhibits126: Exela Pharma Sciences LLC – Product / Service
Exhibits127: Exela Pharma Sciences LLC – Key offerings
Exhibits128: GlaxoSmithKline Plc – Overview
Exhibits129: GlaxoSmithKline Plc – Business segments
Exhibits130: GlaxoSmithKline Plc – Key offerings
Exhibits131: GlaxoSmithKline Plc – Segment focus
Exhibits132: Lupin Ltd. – Overview
Exhibits133: Lupin Ltd. – Product / Service
Exhibits134: Lupin Ltd. – Key news
Exhibits135: Lupin Ltd. – Key offerings
Exhibits136: Merck and Co. Inc. – Overview
Exhibits137: Merck and Co. Inc. – Business segments
Exhibits138: Merck and Co. Inc. – Key news
Exhibits139: Merck and Co. Inc. – Key offerings
Exhibits140: Merck and Co. Inc. – Segment focus
Exhibits141: Mundipharma International Ltd. – Overview
Exhibits142: Mundipharma International Ltd. – Product / Service
Exhibits143: Mundipharma International Ltd. – Key offerings
Exhibits144: Novartis AG – Overview
Exhibits145: Novartis AG – Business segments
Exhibits146: Novartis AG – Key offerings
Exhibits147: Novartis AG – Segment focus
Exhibits148: Shionogi and Co. Ltd. – Overview
Exhibits149: Shionogi and Co. Ltd. – Product / Service
Exhibits150: Shionogi and Co. Ltd. – Key offerings
Exhibits151: Sumitomo Pharma Co. Ltd. – Overview
Exhibits152: Sumitomo Pharma Co. Ltd. – Business segments
Exhibits153: Sumitomo Pharma Co. Ltd. – Key offerings
Exhibits154: Sumitomo Pharma Co. Ltd. – Segment focus
Exhibits155: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits156: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits157: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits158: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits159: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits160: Theravance Biopharma Inc. – Overview
Exhibits161: Theravance Biopharma Inc. – Product / Service
Exhibits162: Theravance Biopharma Inc. – Key offerings
Exhibits163: Viatris Inc. – Overview
Exhibits164: Viatris Inc. – Business segments
Exhibits165: Viatris Inc. – Key offerings
Exhibits166: Viatris Inc. – Segment focus
Exhibits167: Inclusions checklist
Exhibits168: Exclusions checklist
Exhibits169: Currency conversion rates for US$
Exhibits170: Research methodology
Exhibits171: Validation techniques employed for market sizing
Exhibits172: Information sources
Exhibits173: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • BCL-2（B 細胞リンパ腫 2）阻害剤のグローバル市場展望 2023年-2029年：併用療法、単剤療法
  • ペット用がん治療薬のグローバル市場：化学療法、放射線療法、免疫療法、併用療法、その他
  • 喘息治療薬のグローバル市場2023-2030：抗炎症薬、併用療法
  • 骨成長刺激装置のグローバル市場展望 2023年-2029年：誘導結合療法、容量結合療法、併用療法
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(IRTNTR70733-23 )"世界の慢性閉塞性肺疾患治療薬市場2023～2027：併用療法、単剤療法" (英文：Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。